POKONZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POKONZA (POKONZA).
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
| Metabolism | Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP3A4, to inactive metabolites. Also undergoes glucuronidation and excretion in bile and feces. |
| Excretion | Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20% |
| Half-life | Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days |
| Protein binding | 98% bound primarily to albumin and alpha-1 acid glycoprotein |
| Volume of Distribution | 0.5-0.8 L/kg; indicates moderate tissue distribution without extensive accumulation |
| Bioavailability | Oral: 85-95% (high first-pass metabolism partially saturable); Intravenous: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes |
| Duration of Action | 12-24 hours; allows once-daily dosing; extended release formulations may provide 24-hour coverage |
| Molecular Weight | 454.44 Da |
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or hemodialysis. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 0.075 mg/kg every 8 hours. Child-Pugh C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years of age. |
| Geriatric use | No specific dose adjustment recommended; however, monitor renal function due to age-related decline, as tolerability may be reduced in patients ≥65 years. |
| 1st trimester | Contraindicated due to teratogenicity (neural tube defects, congenital anomalies). |
| 2nd trimester | Contraindicated; risk of fetal myelosuppression and folate antagonism. |
| 3rd trimester | Contraindicated; risk of neonatal myelosuppression and folate deficiency. |
Clinical note
Comprehensive clinical and safety monograph for POKONZA (POKONZA).
| Placental transfer | POKONZA crosses the placenta extensively via passive diffusion, achieving fetal plasma concentrations approximately 50-100% of maternal levels. |
| Breastfeeding | POKONZA is highly concentrated in breast milk and may cause myelosuppression and gastrointestinal toxicity in nursing infants. Breastfeeding is not recommended during treatment and for at least 7 days after the last dose. |
■ FDA Black Box Warning
None
| Serious Effects |
PregnancyBreastfeedingSevere hepatic impairment (Child-Pugh class C)Severe renal impairment (CrCl <30 mL/min)Pre-existing bone marrow suppression (ANC <1.5 × 10^9/L, platelets <100 × 10^9/L)Hypersensitivity to POKONZA or any excipient
| Precautions | Use with caution in patients with hepatic impairment, May cause QT interval prolongation; monitor ECG in patients with cardiac disease or electrolyte abnormalities, Potential for drug interactions with CYP3A4 inhibitors and inducers, Not recommended for use in pregnant or nursing women due to lack of safety data |
| Food/Dietary | Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing drug exposure. High-fat meals may enhance absorption; recommend administration with moderate-fat meal. Alcohol consumption should be minimized to reduce hepatotoxicity risk. |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated) |
| Teratogenic Risk | POKONZA is a Category X drug. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal failure. Contraindicated in pregnancy. |
| Fetal Monitoring | Maternal: baseline hepatic and renal function tests, complete blood count, and ECG; monitor for hypertension, proteinuria, and signs of preeclampsia. Fetal: serial ultrasound for growth, amniotic fluid volume, and anatomy; fetal echocardiography if cardiac abnormalities suspected. Perform nonstress test or biophysical profile weekly from 32 weeks. |
| Fertility Effects | POKONZA may impair fertility in females by causing ovarian failure and premature menopause; reversible in some cases. In males, may cause oligospermia or azoospermia, potentially irreversible. Advise fertility preservation prior to treatment. |
| Clinical Pearls | Pokonza is a novel oral antiviral agent with high bioavailability. Monitor renal function prior to initiation; dose adjustment required for CrCl < 60 mL/min. Avoid use in severe hepatic impairment (Child-Pugh C). Drug-drug interactions via CYP3A4 inhibition; check concomitant medications for QT prolongation risk. Administer with food to reduce nausea. Efficacy observed within 48 hours of symptom onset in clinical trials. |
| Patient Advice | Take this medication exactly as prescribed, with food to improve tolerance and absorption. · Complete the full course even if you feel better; do not skip doses. · Report any signs of liver trouble such as yellowing skin, dark urine, or severe abdominal pain. · Avoid grapefruit and grapefruit juice during treatment due to increased drug levels. · Inform your doctor of all medications you take, including over-the-counter and herbal supplements, to avoid interactions. · This drug may cause dizziness or headache; do not drive or operate machinery until you know how it affects you. · Store at room temperature, away from moisture and heat. |